A study of genetic profile and its relation with disease severity in psoriasis patients.

Recruiting

Conditions: Patients with chronic plaque psoriasis

Registration Number: CTRI/2018/03/012552

Lead Sponsor: Dr Bantwal Priya Baliga

Brief Summary: Psoriasis is a chronic inflammatory disease of the skin which affects the skin or joints or both in

adults, with an overall prevalence being 2 to 3% of the population worldwide. This condition has

substantial negative impact on the quality of life of the patients.

1.Clinically it is characterized by well-demarcated, erythematous plaques with silvery white scales.

2.MicroRNA(miRNA) are short, single-stranded, noncoding RNA molecules about 22 to 25 nucleotides in length that are capable of negatively modulating the gene expression by binding to the 3â€™ untranslated region (UTR) of target messenger RNAs (mRNAs), leading to their degradation or translational repression based on the degree of complementarity.

3.Various studies have shown the role of miRNAs in the pathogenesis of psoriasis. Usually miR203,miR21 and miR146a are upregulated , whereas miR125b is down regulated in psoriatic skin compared with that of healthy skin.

4.In peripheral blood mononuclear cells (PBMCs) from patients with psoriasis as compared with healthy controls, miR-193b, miR-223 and miR-143 were found to be significantly upregulated.

5.Many research studies have been conducted to identify soluble biomarkers for psoriasis, but still there is no specific biomarker that can accurately predict the progression of disease and therapeutic response.

AIMS AND OBJECTIVES OF THE STUDY

1.To determine the expression of miRNA223 in cases of chronic plaque psoriasis.

2. To compare the expression of miRNA223 in cases and controls.

3.To correlate the expression of miRNA223 with severity of chronic plaque psoriasis.

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: All

Target Recruitment: 40

Inclusion Criteria

CASES 1.Patients consenting to participate in the study.
2.All chronic plaque psoriasis adult patients above 18 years of age of either gender 3.All chronic plaque psoriasis patients diagnosed clinically or following biopsy will be included.
All chronic plaque psoriasis patients not treated with systemic immunosuppressant in the previous 3 months.
All chronic plaque psoriasis patient not treated with topical immunosuppressant in the previous 2 weeks.
CONTROLS 1.Age and sex matched individuals without chronic plaque psoriasis.

Exclusion Criteria

CASES AND CONTROLS 1.Patients not consenting to participate in the study.
2.Patients with known autoimmune disease, malignancy, or serious chronic systemic disease.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increased expression of miRNA223 in patients with chronic plaque psoriasis	Expression of miRNA223 will be assessed within a period of 18 Months

Secondary Outcome Measures

Name	Time	Method
The expression of miRNA223 can increase with the increase in severity of psoriasis.	estimation of miRNA223 will be done after collection of all cases 18 months from the time of start of study

Trial Locations

Locations (1): K S Hegde Medical Academy
🇮🇳
Kannada, KARNATAKA, India
K S Hegde Medical Academy
🇮🇳Kannada, KARNATAKA, India
Dr Bantwal Priya Baliga
Principal investigator
08242204471
priya.hi@gmail.com